Add like
Add dislike
Add to saved papers

Otolaryngological manifestations and genetic characteristics of lipoid proteinosis.

OBJECTIVES: We investigated the otolaryngological manifestations and genetic characteristics of lipoid proteinosis (LP).

METHODS: Twenty-two cases of LP were included. Multisystem manifestations, pharyngolaryngeal behaviors, and histopathologic and genetic characteristics were evaluated.

RESULTS: All patients presented with hoarseness as the first sign. The onset was in the newborn period in 14 cases. Video-laryngoscopy revealed irregularities along the edges and the surface of the vocal folds with diffuse yellowish deposits. In 18 cases, the oral and pharyngeal mucosa showed yellow-white infiltrates. In all cases, whitish moniliform papules were observed on the upper eyelids. In 18 cases, pocklike scars were present on the face and limbs. Histologically, there were diffuse depositions of hyaline material in the submucosa and dermis that were positive on periodic acid-Schiff staining and negative on Congo red staining. Two patients had homozygous mutations in ECM1 exon 6 and exon 8, and 13 patients had heterozygous mutations in ECM1 exons. Nine patients underwent microlaryngosurgery for excision of deposits in the vocal folds. The voice function was significantly improved after operation.

CONCLUSIONS: Persistent hoarseness from early infancy with laryngeal involvement is the most common feature of LP. Histopathologic characteristics and skin and mucosa changes aid in the diagnosis. Microlaryngosurgery may improve the voice function. Compound heterozygote mutations may be frequent in LP in nonconsanguineous Chinese families.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app